IMVT · Immunovant

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

1000 Park Forty Plaza, Durham, NC, 27713, United States
Biotechnology
Healthcare

Market Cap

6.873B

52 Wk Range

$21.86 - $45.42

Previous Close

$33.21

Open

$33.07

Volume

907,602

Day Range

$32.59 - $34.23

Enterprise Value

5.983B

Cash

722.3M

Avg Qtr Burn

-83.22M

Insider Ownership

55.90%

Institutional Own.

52.76%

Qtr Updated

Sep 30th 2026